Direct-Fed Microbials for E. coli Infection Control in Livestock

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for addressing E. coli-based infections in animals, particularly in livestock, are inadequate due to the rise of antimicrobial resistance, necessitating alternative approaches for prevention and treatment.

Innovation Solution

A composition comprising direct-fed microbials such as Bacillus subtilis strain 3BP5, Bacillus amyloliquefaciens 918, and 15AP4, which can be administered as a feed additive or premix, providing performance benefits like increased bodyweight gain, improved gut barrier integrity, and reduced E. coli shedding.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibiotics are used to treat E. coli-based infections, then infection treatment effectiveness is improved, but antimicrobial resistance develops

Engineering Contradiction:
Improveinfection treatment effectivenessVSAvoidantimicrobial resistance
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses Bacillus-based direct-fed microbials as an intermediary substance to treat E. coli infections. These microbials produce antimicrobial substances that indirectly combat E. coli without using traditional antibiotics, thereby treating infections while avoiding the development of antimicrobial resistance. The Bacillus microbials act as a mediator that provides therapeutic effect through natural antimicrobial production rather than direct antibiotic application.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If traditional E. coli infection treatment methods are used, then infection control is achieved, but alternative approaches are needed due to resistance

Engineering Contradiction:
Improveinfection controlVSAvoidneed for alternative approaches
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the fundamental parameter of treatment approach by switching from antibiotic-based therapy to Bacillus-based direct-fed microbial therapy. This parameter change provides a versatile alternative treatment method that maintains infection control effectiveness while addressing the limitations of traditional antibiotics through a different mechanism of action involving microbial competition and natural antimicrobial production.

Inventive Principle:
Principle #35Parameter changes

3Object-affected harmful factors

If E. coli is shed into the environment, then transmission to other animals occurs, but shedding can be reduced through treatment

Engineering Contradiction:
ImproveE. coli transmissionVSAvoidinfection spread
Core Design Contradiction:
Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent converts the harmful effect of E. coli shedding into a benefit by using Bacillus microbials that produce antimicrobial substances. These substances reduce E. coli shedding by competing with and inhibiting E. coli in the gut environment, thereby transforming the situation where E. coli is naturally shed into one where the shedding is controlled and reduced, protecting other animals from transmission.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentEP3762000B1Use of direct- fed microbials in preventing and/or treating e. coli-based infections in animals
Publication Date: 2024.10.02 INT N&H DENMARK APS
  • EP3762000B1 patent drawingFigure 1

AI summary

A composition and method for preventing and/or treating an E. coli-based infection in an animal is described.